This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Celgene Corporation. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Gilles Buchwalter: Innovator in Combination Therapies
Introduction
Gilles Buchwalter is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of combination therapies.
Latest Patents
Buchwalter holds a patent for "Combination therapies comprising apremilast and Tyk2 inhibitors." This patent outlines methods for treating diseases and disorders responsive to the inhibition of PDE4 by administering apremilast alongside a Tyk2 inhibitor to a subject. Additionally, it includes pharmaceutical compositions that combine these two agents.
Career Highlights
Buchwalter is associated with Celgene Corporation, a leading biopharmaceutical company known for its innovative therapies. His work focuses on advancing treatment options for various diseases, showcasing his commitment to improving patient outcomes.
Collaborations
He has collaborated with esteemed colleagues such as Peter Henry Schafer and Robert Plenge, contributing to a rich environment of innovation and research.
Conclusion
Gilles Buchwalter's work in combination therapies exemplifies the impact of innovative thinking in the pharmaceutical industry. His contributions continue to pave the way for new treatment possibilities.